We are live on ! Find out more
FC

Finepoint Capital Portfolio holdings

AUM $1.95B
1-Year Est. Return 45.61%
This Fund
S&P 500
This Quarter Est. Return
-2.31%
1 Year Est. Return
+45.61%
3 Year Est. Return
+24.83%
5 Year Est. Return
+26.66%
10 Year Est. Return
–
AUM
$309M
AUM Growth
+$5.25M
Cap. Flow
+$5.62M
Cap. Flow %
1.82%
Top 10 Hldgs %
59.65%
Holding
61
New
4
Increased
8
Reduced
7
Closed
17

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$15.2M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$14.5M
3
RLAY icon
Relay Therapeutics
RLAY
+$13.7M
4
SWTX
SpringWorks Therapeutics
SWTX
+$8.25M
5
APLS
Apellis Pharmaceuticals
APLS
+$3.65M

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$16.9M
2
ARGX icon
argenx
ARGX
+$10.2M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.98M
4
ASTL icon
Algoma Steel
ASTL
+$3.26M
5
FOLD
Amicus Therapeutics
FOLD
+$2.93M

Sector Composition

Rank Sector Weight
1 Healthcare 89.87%
2 Materials 6.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REVHW
51
DELISTED
Revolution Healthcare Acquisition Corp. SAIL Warrant.
REVHW
– –
-432,639
Closed -$17K
WPCA.WS
52
DELISTED
Warburg Pincus Capital Corporation I-A Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
WPCA.WS
– –
-14,999
Closed -$1K
WPCB.WS
53
DELISTED
Warburg Pincus Capital Corporation I-B Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
WPCB.WS
– –
-125,000
Closed -$8K
CRHC.WS
54
DELISTED
Cohn Robbins Holdings Corp. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
CRHC.WS
– –
-904,000
Closed -$21K
SPGS.WS
55
DELISTED
Simon Property Group Acquisition Holdings, Inc. Warrants, each exercisable for one Class A common stock at an exercise price of $11.50 per share
SPGS.WS
– –
-335,200
Closed -$22K
HAACW
56
DELISTED
Health Assurance Acquisition Corp. Warrants
HAACW
– –
-643,000
Closed -$19K
GBTG.WS
57
DELISTED
Global Business Travel Group, Inc. Warrants, each exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share
GBTG.WS
– –
-913,000
Closed -$1.43M
TMAC.WS
58
DELISTED
The Music Acquisition Corporation Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50
TMAC.WS
– –
-75,250
Closed -$3K
FVT.WS
59
DELISTED
Fortress Value Acquisition Corp. III Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share
FVT.WS
– –
-225,000
Closed -$23K
FVIV.WS
60
DELISTED
Fortress Value Acquisition Corp. IV Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share
FVIV.WS
– –
-306,513
Closed -$54K
1 2
3

Similar funds

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return

Finepoint Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Finepoint Capital held 61 positions worth $309M, up 1.7% from $304M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Finepoint Capital's Q4 2022 filing shows 4 new, 8 increased, 7 reduced and 17 closed positions. Its largest new stake was Sarepta Therapeutics: 131,457 shares worth $17M. The largest sale was Arcus Biosciences, an estimated $16.9M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier, followed by Materials.

  • Finepoint Capital's largest Q4 2022 buy was Sarepta Therapeutics: 131,457 shares worth $17M.
  • Finepoint Capital added most to SpringWorks Therapeutics in Q4 2022, an estimated $8.25M increase.
  • Finepoint Capital's biggest Q4 2022 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $5.98M.
  • Finepoint Capital fully exited Arcus Biosciences in Q4 2022, selling an estimated $16.9M.
  • Finepoint Capital's ten largest holdings make up 60% of its $309M portfolio in Q4 2022.
  • Finepoint Capital opened 4 new positions and closed 17 in Q4 2022.
  • Finepoint Capital's portfolio value rose 1.7% quarter-over-quarter to $309M.

Based on Finepoint Capital's 13F filing for Q4 2022, filed 13 Feb 2023.